Andolast free base

Cat. No.: HY-106358

CAS No.: 132640-22-3

Molecular Formula: $C_{15}H_{11}N_9O$

Molecular Weight: 333.31

Target: Phosphodiesterase (PDE)

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (150.01 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	3.0002 mL	15.0010 mL	30.0021 mL
5 mM	0.6000 mL	3.0002 mL	6.0004 mL
10 mM	0.3000 mL	1.5001 mL	3.0002 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (7.50 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Andolast (CR 2039) (free base) is an anti-allergic agent. Andolast can inhibit cAMP-phosphodiesterase with an IC_{50} value of 50 μM. Andolast can be used for the research of asthma[1].

In Vivo

Andolast (CR 2039) (i.v. or i.m.) inhibits rat passive cutaneous anaphylaxis (PCA) with an ED_{50} of 0.1 mg/kg[1].
CR 2039 (10-100 mg/kg; i.v. or i.m.) inhibits the microvascular permeability changes in a model of allergic conjunctivitis in sensitized guinea-pigs[1].
CR 2039 (0-1000 μM; i.v.) inhibits dose dependently guinea-pig lung cAMP-phosphodiesterase with an IC_{50} value of 50 μM[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Hartley guinea-pigs (300-500 g) [1]

Dosage:	10-100 mg/kg
Administration:	I.M; I.V.
Result:	Showed dose-related significant protection against lgE-dependent bronchial anaphylaxis induced by aerosolized antigen in anesthetized guinea-pigs. Delayed dose dependently the onset of bronchoconstriction induced by aerosolized antigen.

REFERENCES

[1]. Revel L, Colombo S, Ferrari F, Folco G, Rovati LC, Makovec F. CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma. Eur J Pharmacol. 1992;229(1):45-53.

[2]. Czuczwar SJ, Gasior M, Kozicka M, Pietrasiewicz T, Turski WA, Kleinrok Z. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. Eur Neuropsychopharmacol. 1998;8(3):233-238.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA